Housed since 1996 in Bulle, in the heart of Gruyère, UCB has invested approximately CHF 500 million to date in the site, which features advanced industrial equipment at the forefront of innovation and technology.
The biotechnological production unit opened in October 2014 allows UCB to provide treatments to patients suffering from rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial pondylarthrite and Crohn’s disease.
The Bulle site is certified by the environmental standards ( ISO 14001 ) and standards of safety and health at work ( OHSAS 18001 ) and is regularly inspected for quality compliance by various health authorities worldwide, such as Swissmedic , Food & Drug Administration (FDA) and the Japanese authorities (PMDA).
The Swiss site comprises three legal entities:
– UCB SA Farchim
– UCB-Pharma AG (commercial subsidiary to the Swiss market)
– UCB SA Medical Devices
The Bulle site currently has more than 400 members of staff .
Contact
UCB Farchim SA
Zone Industrielle de Planchy d’Avau
Chemin de Croix Blanche , 10
CH – 1630 Bulle
Tel: +00 41 26 919 0200
Fax: +00 41 26 919 0240
UCB Pharma AG
Zone Industrielle de Planchy d’Avau
Chemin de Croix Blanche , 10
CH – 1630 Bulle
Tel: +00 41 26 919 0180
Fax: +00 41 26 919 0181
Contact persons: Catherine Sauteur
One of the doyens of European biotech is stepping back from general management. Jean-Paul Clozel founded rare disease focused Actelion along with his wife Martine Clozel in 1997, a company…
The latest news from Swiss pharma and biotech including a new CEO appointment for leading CDMO Lonza, promising Phase III readouts from Novartis’ latest leukaemia drug at ASCO, Roche’s pivot…
While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022…
The biggest pharma news from Switzerland, including the industry’s cautious reaction to a new free trade deal with India; the drop in Roche’s share prices; Novartis’ acquisiton of MorphoSys, and…
For the Swiss Agency for Therapeutic Products (Swissmedic), one of the world’s leading regulatory authorities, 2023 was an important year. Not only did the agency gain recognition from the World…
Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to…
2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges…
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Executive…
The latest news from Swiss pharma and healthcare, including the startling announcement that Switzerland is set to destroy a full nine million doses of expired Moderna COVID-19 vaccines, with over…
Roche slipped from second to fifth place in this year’s ranking of the world’s top pharmaceutical companies, reported uninspiring numbers for the first half of the year and seen its…
See our Cookie Privacy Policy Here
